Baili Tianheng Company's Baili Pharmaceutical was singled out by the Yunnan Provincial Medical Insurance Bureau for its high-priced oral solution of 558 yuan.

On September 24, the Yunnan Province Medical Insurance Bureau issued a public inquiry letter to Sichuan Bailing Pharmaceutical Co., Ltd., a subsidiary of Bailing Tianhengzi Company, regarding its pricing of the orally disintegrating solution of Enalapril Maleate, which was listed on the market at as high as 558 yuan, a nearly 70-fold price difference from other formulations with the same generic name. The bureau requested the company to provide a public response. The Yunnan Province Medical Insurance Bureau asked Bailing Pharmaceutical to address whether there was any involvement in raising the listing price through agents, engaging in unfair marketing practices, and subsequently increasing the burden on patients and medical insurance funds during the sales process of the Enalapril Maleate orally disintegrating solution.